Human FAF1 activation kit by CRISPRa

CAT#: GA107650

FAF1 CRISPRa kit - CRISPR gene activation of human Fas associated factor 1



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (3)
FAF1 mouse monoclonal antibody, clone OTI10D1 (formerly 10D1)
    • 100 ul

CNY 1,999.00
CNY 2,700.00


FAF1 (Myc-DDK-tagged)-Human Fas (TNFRSF6) associated factor 1 (FAF1)
    • 10 ug

CNY 4,840.00


FAF1 mouse monoclonal antibody, clone OTI2F9 (formerly 2F9)
    • 30 ul

CNY 800.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol FAF1
Locus ID 11124
Kit Components

GA107650G1, FAF1 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA107650G2, FAF1 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA107650G3, FAF1 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_007051, NM_131917
Synonyms CGI-03; hFAF1; HFAF1s; UBXD12; UBXN3A
Summary Interaction of Fas ligand (TNFSF6) with the FAS antigen (TNFRSF6) mediates programmed cell death, also called apoptosis, in a number of organ systems. The protein encoded by this gene binds to FAS antigen and can initiate apoptosis or enhance apoptosis initiated through FAS antigen. Initiation of apoptosis by the protein encoded by this gene requires a ubiquitin-like domain but not the FAS-binding domain. [provided by RefSeq, Jul 2008]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...